---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014777"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:31:02.418747+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences reports Q2 net loss of $15.1M; FDA clears IND for TYRA-300

## Summary
- Q2 2022 net loss $15.1M vs $5.5M in Q2 2021; R&D expense $12.0M vs $4.4M.
- Cash and cash equivalents $275.1M as of June 30, 2022, sufficient to fund operations.
- FDA cleared IND for TYRA-300 (FGFR3 inhibitor) to begin Phase 1/2 SURF301 study in metastatic urothelial carcinoma.
- IND for TYRA-200 (FGFR2 inhibitor) on track for submission in 2H 2022 with initial focus on intrahepatic cholangiocarcinoma.
- Key leadership hires: Sarah Honig (VP Corp Dev) and Ali Fawaz (General Counsel/Secretary).

## SEC filing metadata
- accession: 0000950170-22-014777
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017022014777/0000950170-22-014777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017022014777/tyra-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014777
- JSON: https://secwatch.observer/filing/0000950170-22-014777.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.